NCT05153434Phase 2Completed

A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

Study sponsor: Aardvark Therapeutics, Inc. · AARD

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-09-24Actual
Enrollment · participants19Actual
Source updated2026-09-08Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Incidence of Treatment-Emergent Adverse Events (TEAE). After: Measure: Incidence of Treatment Emergent Adverse Events (TEAE).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview